IDENTIFICATION OF A NEW VARIANT CYP2D6 ALLELE LACKING THE CODON ENCODING LYS-281 - POSSIBLE ASSOCIATION WITH THE POOR METABOLIZER PHENOTYPE

被引：150

作者：

TYNDALE, R ^{[1
]}

AOYAMA, T ^{[1
]}

BROLY, F ^{[1
]}

MATSUNAGA, T ^{[1
]}

INABA, T ^{[1
]}

KALOW, W ^{[1
]}

GELBOIN, HV ^{[1
]}

MEYER, UA ^{[1
]}

GONZALEZ, FJ ^{[1
]}

机构：

[1] UNIV TORONTO,CTR MED SCI,DEPT PHARMACOL,TORONTO M5S 1A1,ONTARIO,CANADA

来源：

PHARMACOGENETICS | 1991年 / 1卷 / 01期

关键词：

D O I：

10.1097/00008571-199110000-00005

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

A variant CYP2D6(C) P450 protein was found in a liver characterized by deficient microsomal metabolism of bufuralol and sparteine, prototypical substrates for the debrisoquine-sparteine drug oxidation polymorphism. This protein was present at decreased levels in liver and had a slightly different relative mobility on SDS-polyacrylamide gels. The cDNA cloning and sequencing of the variant, designated CYP2D6(C), revealed that its mRNA lacked a single codon resulting in deletion of Lys281. This was the result of a three base pair deletion at the 3' end of CYP2D6 exon 5. The CYP2D6(C) P450, produced in HepG2 cells using vaccinia virus mediated cDNA expression displayed Km values toward bufuralol, debrisoquine and sparteine that were not significantly different from wild type CYP2D6. These data suggest that the poor metabolizer phenotype in livers expressing CYP2D6(C) is not due to a catalytically defective enzyme but perhaps due to decreased levels of the P450 protein in microsomal membranes. Low microsomal CYP2D6(C) contents could result from deficient membrane insertion or decreased stability of the P450 protein. A polymerase chain reaction-based procedure, developed to detect CYP2D6(C) alleles, indicates that this variant probably represents less than 1.5% of all CYP2D6 alleles.

引用

页码：26 / 32

页数：7

共 29 条

[1]

Chakrabarti S., Brechling K., Moss B., Vaccinia virus expression vector: Co-expression of jS-galactosidase provides visual screening of recombinant virus plaques, Mol Cell Biol, 5, pp. 3403-3409, (1985)

[2]

Deininger P.L., Random subcloning of sonicated DNA: Application to shotgun DNA sequence analysis, Anal Biochem, 129, pp. 216-223, (1983)

[3]

Distlerath L.M., Reilly P., Martin M.V., Davis G.G., Wilkinson G.R., Guengerich F.P., Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphisms in oxidative drug metabolism, J Biol Chem, 260, pp. 9057-9067, (1985)

[4]

Eichelbaum M., Gross A.S., The genetic polymorphism of debrisoquine-sparteine metabolism: Clinical aspects, Pharmacol Ther, 46, pp. 377-394, (1990)

[5]

Gaedigk A., Blum M., Gaedik R., Eichelbaum M., Meyer U.A., Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism, Am J Hum Genet, 48, pp. 943-950, (1991)

[6]

Gonzalez F.J., The molecular biology of cytochrome P450s, Pharmacol Rev, 40, pp. 243-288, (1988)

[7]

Gonzalez F.J., Skoda R.C., Kimura S., Umeno M., Zanger U.M., Nebert D.W., Gelboin H.V., Hardwick J.P., Meyer U.A., Characterization of the common genetic defect in humans deficient in debriso- quine metabolism, Nature, 331, pp. 442-445, (1988)

[8]

Gonzalez F.J., Vilbois F., Hardwick J.P., Mc Bride O.W., Nebert D.W., Gelboin H.V., Meyer U.A., Human debrisoquine 4-hydroxylase (P450IID1): CDNA and deduced amino acid sequences and assignment of the CYP2D6 locus to chromosome 22, Genomics, 2, pp. 174-179, (1988)

[9]

Gonzalez F.J., Aoyama T., Gelboin H.V., Expression of mammalian cytochrome P450 using vaccinia virus, Methods Enzymol

[10]

Guengerich F.P., Enzymatic oxidation of xenobiotic chemicals, Crit Rev Biochem Mol Biol, 25, pp. 97-153, (1990)

← 1 2 3 →